Navigation Links
Dalton and AdeTherapeutics Enter Into a Manufacturing Services Agreement
Date:1/6/2011

TORONTO, Jan. 6, 2011 /PRNewswire/ -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Clinical Manufacturing Services Agreement with AdeTherapeutics (a day' therapeutics), Inc., a specialty pharma company based in Saskatoon, Saskatchewan, focused on providing quality therapeutic options in inflammation and acute care medicine. Dalton will provide aseptic fill/finish services under cGMP, for ADE's sterile anti-adhesion (scar tissue reduction) product.

"Our Establishment License from Health Canada, combined with our expert capabilities in analytical services and aseptic manufacturing, solidified the manufacturing agreement," said Peter Pekos, President and CEO. "Dalton is pleased to add this strategic relationship to our growing list of innovative pharmaceutical clients.  We are thrilled to be working with AdeTherapeutics and look forward to rapidly moving their product through their key milestones," continued Pekos.

Sanj Singh, President and Chief Executive Officer of AdeTherapeutics remarked, "The partnership with Dalton is a key part of AdeTherapeutics capital efficient virtual drug development model where we work with expert service providers from all over the globe to rapidly bring our novel therapeutics and diagnostics forward benefiting the healthcare community with safe, reliable and cost-effective treatment choices. We are excited about the opportunity to partner with a company whose client focus and commitment to quality match our own. Sharing these values with partners like Dalton is vital to our ability to provide products which fulfill the therapeutic needs of physicians and their patients. Surgeries are expected to double in the next five years and with no established standard of care, we are optimistic that our lead anti-adhesion candidate can solve this high unmet medical need."

About Dalton

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and aseptic filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients. Further information can be found at http://www.dalton.com.

About AdeTherapeutics, Inc.

AdeTherapeutics, Inc. is a privately-held clinical-stage drug development company headquartered in Saskatoon, SK.  Focused in the areas of inflammation and acute care medicine, AdeTherapeutics' business strategy is to build a robust portfolio of high value products by developing and/or in-licensing clinical-stage ready therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. The Company's most advanced therapeutic is a safe and effective anti-adhesion product that significantly reduces scar tissue adhesions caused by surgeries.


'/>"/>
SOURCE Dalton Pharma Services
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dalton Pharma Services Announces Successful Completion of Health Canada Inspection
2. Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services
3. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
4. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
5. UAS Laboratories Enters Into Agreement to Launch New Probiotic Product at Expo West
6. HRC Medical Center Offers Patients Relief with Innovative Bio-Identical Hormone Replacement Therapy
7. Zenobia Therapeutics, Inc. Enters Into a Research Collaboration With Lundbeck for the Parkinsons Disease Target LRRK2
8. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
9. Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share
10. Worlds smallest battery created at CINT nanotechnology center
11. Shrink Nanotechnologies Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):